Key facts
- It has raised $16.3M; the latest was Accelerator/Incubator in Oct 2025.
- Notable investors include Creative Destruction Lab, Picus Capital, Alven Capital Partners, Memorial Sloan Kettering Cancer Center, Jens Begemann — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for StratifAI
- ·The full record, as it builds
Funding rounds
No funding rounds for StratifAI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About StratifAI
Developer of a precision oncology platform designed to advance cancer diagnostics through next-generation biomarker discovery. The company offers a multimodal AI discovery platform that identifies prognostic and predictive biomarkers from clinical data and assesses metastatic risk in early breast cancer from digitized histology slides, enabling clinicians in solid-tumor oncology to refine treatment strategies with greater accuracy and equity.
- Sector
- Healthcare
- HQ
- Berlin, Germany
- Founded
- 2023
- Employees
- 18
- Website
- stratifai.com/
- Ownership
- Privately Held (backing)
StratifAI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in StratifAI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on StratifAI in its N-PORT filings yet. We sweep new filings monthly.